Key result
Intracellular angiotensinogen is hypothesized to bind and inactivate the retinoblastoma tumor suppressor protein, potentially contributing to the pathogenesis of hypertension.
Answers are grounded in this paper and cite their sources.
Presents a novel molecular hypothesis linking angiotensinogen and retinoblastoma tumor suppressor protein in the pathogenesis of hypertension, suggesting a new potential therapeutic target.
Hypertension ranks among the most important disease challenges on a global scale. Here, a novel hypothesis is presented which implicates angiotensinogen, i.e. the precursor protein for the hypertensive peptide angiotensin II, as a key culprit in the pathogenesis of hypertension. This hypothesis more precisely entails that intracellular angiotensinogen binds and thereby inactivates the retinoblastoma tumor suppressor protein (RB), consequently leading to an inflammatory and hyperproliferative state that significantly contributes to pathologically increasing blood pressure. Accordingly, a conceivable antihypertensive strategy could comprise RB-derived compounds that neutralize angiotensinogen.
No takes yet. Share an insight, caveat, or question.
Radulescu (2012) conducted a letter in Hypertension. Angiotensinogen was evaluated. Intracellular angiotensinogen is hypothesized to bind and inactivate the retinoblastoma tumor suppressor protein, potentially contributing to the pathogenesis of hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: